56 completed, 22 recruiting, 18 terminated, 16 withdrawn. 122 Phase 2, 19 Phase 1, 8 Phase 3.
Follow Jazz Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer Lurbinectedin, Osimertinib - Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Misty Shields | 16 | 2027-01-01 | 2026-10-15 |
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| A Study of ONC201 for Refractory Meningioma ONC201 - Meningioma, Refractory Meningioma | Phase 2 | Withdrawn | University of Nebraska | 2026-12-01 | 2026-01-26 | |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-10-06 |
| Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome Epidiolex 100 mg/mL Oral Solution - Sturge - Weber Syndrome (SWS) | Phase 2 | Recruiting | Johns Hopkins University | 10 | 2026-09-17 | 2026-10-02 |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas Tislelizumab, Leucovorin, Oxaliplatin - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | American Association for Cancer Research | 242 | 2026-07-20 | 2026-10-05 |
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma JZP3507 - Meningioma | Phase 2 | Recruiting | Jazz Pharmaceuticals | 30 | 2026-07-16 | 2026-10-29 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients Zanidatamab, Pembrolizumab, mFOLFOX - Gastroesophageal Adenocarcinoma, First Line Therapy | Phase 2 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 80 | 2026-01-16 | 2026-06-30 |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma ONC206, ONC206: Dose 1, ONC206: Dose 2 - Advanced Pheochromocytoma and Paraganglioma, PCPG | Phase 2 | Recruiting | Jazz Pharmaceuticals | 90 | 2026-01-02 | 2026-10-29 |
| Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene. Zanidatamab - Non-Small Cell Lung Cancer, Sarcoma | Phase 2 | Recruiting | UNICANCER | 105 | 2025-10-30 | 2025-12-19 |
| Study of Cannabidiol and Neuroimaging on Stress Cannabidiol, Placebo - Early Life Adversity, Trauma | Phase 1 / Phase 2 | Recruiting | Icahn School of Medicine at Mount Sinai | 160 | 2025-10-29 | 2026-09-10 |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer Zanidatamab, Paclitaxel, Docetaxel - HER2-positive Breast Cancer, Breast Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 125 | 2025-09-24 | 2026-10-29 |
| Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals With Fragile-X Syndrome CBD Oral Solution, Placebo - Fragile X Syndrome | Phase 2 | Recruiting | Université de Sherbrooke | 40 | 2025-09-01 | 2026-08-28 |
| Effect of CBD on the Brain CBD Oral Solution (eCBD system Target), Placebo - Fragile X Syndrome | Phase 2 | Not yet recruiting | Université de Sherbrooke | 50 | 2025-05-01 | 2025-02-17 |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Zanidatamab - Breast Cancer, Gastric Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 200 | 2025-01-14 | 2026-07-10 |
| Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas Lurbinectedin, Radiotherapy, Non-investigational surgery - Locally Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Withdrawn | University of California, San Francisco | 2024-10-31 | 2024-11-18 | |
| Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Defibrotide - Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma | Phase 2 | Withdrawn | University of California, San Francisco | 2024-08-01 | 2024-08-07 | |
| Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma Paclitaxel, Ramucirumab, Zanidatamab - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 168 | 2024-04-16 | 2026-08-11 |
Showing 20 of 122. Sign in to see all of them.
Leukemia, Myeloid, Acute (17) · Epilepsy (9) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (9) · Colorectal Neoplasms (5) · Recurrence (5) · Autism Spectrum Disorder (4) · Breast Neoplasms (4) · Disorders of Excessive Somnolence (4) · Leukemia (4) · Neoplasm Metastasis (4) · Neoplasms (4) · Parkinson Disease (4) · Sarcoma (4) · Burkitt Lymphoma (3) · Essential Tremor (3)
CPX-351 (17) · Cytarabine (13) · Cannabidiol (12) · zanidatamab (11) · PM 01183 (9) · Daunorubicin (7) · TIC10 compound (7) · brincidofovir (7) · Injections (6) · Sodium Oxybate (6) · defibrotide (6) · nabiximols (6) · solriamfetol (5) · Liposomes (4) · asparaginase erwinia chrysanthemi recombinant (4)
United States (88) · Spain (18) · United Kingdom (17) · Canada (15) · Germany (10) · Poland (9) · France (8) · Italy (7) · Netherlands (7) · Israel (3) · South Korea (3) · Sweden (3) · Australia (2) · Austria (2) · Belgium (2)
Anne M Comi, MD (2) · Grace Wang, MD (2) · Jan Ramaekers, PhD (2) · Stephen Marcus, MD (2) · Aaron Ellenbogen, DO (1) · Alexander Stein, Prof. Dr. (1) · Allen Mellemed, MD (1) · Anastasia Vishnevetsky, MD, PhD (1) · Andy M Trotti, MD (1) · Arthur Louie, MD (1) · Bengt Bergstrom, Md, PhD (1) · Beverly Benson, PhD (1) · Bijal Shah, M.D. (1)
PMID 27851688, PMID 33623076, PMID 36494591, PMID 38335473, PMID 20209489, PMID 20435443, PMID 22364685, PMID 24066743, PMID 24687088, PMID 26298786, PMID 26376459, PMID 27166238, PMID 27573936, PMID 28063938, PMID 31098682, PMID 31109198, PMID 31244760, PMID 31456142, PMID 32350749, PMID 32652616, PMID 33750072, PMID 33998885, PMID 34003586, PMID 34191352, PMID 35157764, PMID 35244208, PMID 36108304, PMID 36519326, PMID 36877132, PMID 37195023, PMID 37231094, PMID 37276871, PMID 37399456, PMID 39114870, PMID 39454281, PMID 40339592, PMID 40473445, PMID 40656115
2014 (5), 2025 (4), 2015 (3), 2019 (2), P30CA015704 (1), R01MH139940 (1), R01NS124607 (1)